Dope Named Global IP Star Company for Groundbreaking Decellularization Technology

Domestic bio company DOF, selected as 'Global IP Star Company' for its innovative technology...accelerating entry into the global market DOF, a domestic bio company and a leader in the field of biological tissue implants, has been finally selected as a 'Global IP Star Company' by the Korean Intellectual Property Office (KIPO) and the Korea Institute of Patent Information (KIPI), signaling a green light for its entry into the global market. This achievement is evaluated as a result of national recognition for DOF's independently developed innovative technology and the excellence of its robust intellectual property (IP) portfolio. The 'Global IP Star Company' program is a key national R&D program that provides intensive support for securing overseas IP and establishing IP strategies for 3 years, targeting domestic small and medium-sized enterprises (SMEs) with high export potential. This year, promising hidden champions with advanced technology and a solid IP foundation were selected after fierce competition, adding more significance to the program. DOF's core competitiveness lies in its independent development of 'E-CELL®', the world's first supercritical carbon dioxide (CO₂) fluid-based decellularized human tissue manufacturing technology. This technology transcends the limitations of conventional chemical processes, effectively removing cells while perfectly preserving key components of human tissue such as the extracellular matrix (ECM), growth factors, and complex tissue structures. Applicable to various tissues including skin, bone, cartilage, and nerves, E-CELL® is harmless to the human body by utilizing eco-friendly carbon dioxide. Embracing the three core values of 'Extracting Cell', 'Eco-friendly', and 'Economic', it is gaining recognition as a next-generation bio-processing technology suitable for the ESG era. With this selection as a 'Global IP Star Company', DOF will receive comprehensive government support, including strengthening its overseas patent portfolio, developing brands and designs, and establishing IP risk response strategies. Leveraging this as a stepping stone, DOF plans to further concretize and accelerate its global market entry strategy. For DOF, which aims for a technology-focused special listing this autumn based on the originality and commercial viability of its E-CELL® technology, this selection is expected to be a crucial turning point for strong external validation of the company's technological prowess. A DOF official stated, "E-CELL® is a brand that embodies an ESG management philosophy that prioritizes humans and the environment, beyond just outstanding technology. We will use the selection as a Global IP Star Company as an opportunity to further advance our IP strategy and solidify DOF's competitive advantage in the global market." The official also emphasized the aspiration to "leap forward as a true global bio leader company through a successful listing."